Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICAT: CD25/71 Allodepleted Donor T Cells After SCT
NCT01827579Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2014
- Primary completion
- Jan 2020
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allodepleted donor T cells in haematological malignancies (2 arms), sponsored by University College London. Primary endpoint: Circulating CD3+ve T cell count at 4 months. Started Jul 2014; status: completed.
02
Drugs
allodepleted donor T cells
03
Conditions
haematological malignancies
Beyond the preview
Go deeper on NCT01827579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827579.